• Molecular NameTerazosin
  • SynonymAbbott 45975; Terazosin HCl; Terazosin hydrochloride; Terazosina [INN-Spanish]; Terazosine; Terazosine [INN-French]; Terazosinum [INN-Latin]; Trazosin HCl
  • Weight387.44
  • Drugbank_IDDB01162
  • ACS_NO63590-64-7
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)1.0
  • pka7.1 (0.1 M sodium hydroxide)
  • LogD (pH=7, predicted)0.44
  • Solubility (experiment)29.7 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-2.49
  • LogSw (predicted, AB/LogsW2.0)2.94
  • Sw (mg/ml) (predicted, ACD/Labs)0.95
  • No.of HBond Donors2
  • No.of HBond Acceptors9
  • No.of Rotatable Bonds4
  • TPSA103.04
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA selective alpha 1 antagonist used for treatment of symptoms of an enlarged prostate (BPH). It also acts to lower the blood pressure, and is therefore a drug of choice for men with hypertension and prostate enlargement.
  • Absorption_value90.0
  • Absorption (description)Essentially completely absorbed in man (90% bioavailability).
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding92.0
  • Volume of distribution (VD)1.1 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic. One of the four metabolites identified (piperazine derivative of terazosin) has antihypertensive activity.
  • Half life9~12 h
  • ExcretionN/A
  • Urinary Excretion11~14
  • Clerance1.1~1.2 ml/min/kg
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=259.3 mg/kg (IV)